Newbury Pharmaceuticals Wins Swedish Approval for Generic Prukalopride Newbury
Newbury Pharmaceuticals has received marketing authorization for Prukalopride Newbury in Sweden, with no further country approvals planned for now.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Newbury Pharmaceuticals AB has obtained marketing authorization for Prukalopride Newbury 1 mg and 2 mg film-coated tablets in Sweden, according to a company statement distributed via TradingView. The company said no other country approvals are planned at this time.
The product is a generic version of Resolor, a selective 5-HT4 receptor agonist for symptomatic treatment of chronic constipation in adults when laxatives fail to give adequate relief. DLMI Nordic Pharma Insights estimates the current annual value of the Swedish market at 0.58 million euros. CEO Karl Karlsson linked the approval to a strategic partnership announced in March 2026.
why it matters
For broader markets the news is minor: the Swedish segment is small, and the company is listed on Nasdaq First North. For investors it mainly signals portfolio growth in the Nordics and a planned launch in the near future.
tags
instruments
sources
- Newbury Pharmaceuticals Gets Prukalopride Newbury Approval — Reuters, 27 October 2026 at 16:01 UTC
- Newbury Pharmaceuticals Secures Generic Approval for Prukalopride Newbury — TradingView, 27 October 2026 at 16:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗